HealthcareServices

CC Chemokine Receptor Type 5 Market 2026–2030: Forecast, Innovation, and Competitive Trends

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cc chemokine receptor type 5 market from 2026–2035 with trusted insights from The Business Research Company

By how much is the CC Chemokine Receptor Type 5 Market expected to grow between 2026 and 2030?

The cc chemokine receptor type 5 market size has experienced considerable expansion in recent years. It is forecast to rise from $1.54 billion in 2025 to $1.7 billion in 2026, with a compound annual growth rate (CAGR) of 10.1%. The market’s historical growth can be attributed to several factors, including the discovery of CCR5’s role in HIV infection, the early development of CCR5 inhibitors, the expansion of immunology research programs, clinical trials focusing on inflammatory diseases, and the increasing adoption of targeted receptor therapies.

The cc chemokine receptor type 5 market is projected to experience substantial growth over the next few years. It is expected to expand to $2.48 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.9%. This anticipated growth is driven by the expansion of personalized immunotherapies, increasing innovation in HIV treatment, a rise in oncology drug development pipelines, growing investment in immune modulation research, and advancements in targeted receptor drug design. Furthermore, key trends in the forecast period include the increasing development of CCR5 antagonist therapies, a rising focus on HIV and immunology research, the expansion of CCR5 applications in oncology, growing adoption of targeted immune modulation, and an enhanced emphasis on precision drug development.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18290&type=smp

Which Drivers Are Influencing Market Acceleration In The CC Chemokine Receptor Type 5 Market?

The CC chemokine receptor type 5 market is projected to expand in the future, driven by the rising occurrence of chronic diseases. Chronic illnesses are defined as enduring health conditions, including ailments like heart disease, diabetes, and arthritis, which typically advance gradually and necessitate continuous care. The rise in chronic disease prevalence stems from an aging global population and a surge in lifestyle-associated risk factors, such as unhealthy eating habits, lack of exercise, and obesity. CC Chemokine Receptor Type 5 (CCR5) plays a vital role in chronic conditions like human immunodeficiency virus (HIV), functioning as a coreceptor that enables the virus to penetrate and infect immune cells, thereby significantly contributing to the disease’s advancement. For example, data from April 2025 by the Centers for Disease Control and Prevention (CDC), a US-based federal agency, indicated that in 2023, roughly 194 million U.S. adults, representing 76.4% of the adult population, reported at least one chronic ailment. This prevalence rate was 59.5% for young adults, 78.4% for midlife adults, and 93.0% for older adults. Consequently, the expanding occurrence of chronic diseases is stimulating the expansion of the CC chemokine receptor type 5 market.

What Leading Segments Are Studied In The CC Chemokine Receptor Type 5 Market?

The cc chemokine receptor type 5 market covered in this report is segmented –

1) By Type: BMS-813160, AG-1105, DS-001, Other Types

2) By Distribution Channel: Hospitals, Clinics

3) By Application: Infectious Disease, Immunology, Oncology, Other Applications

4) By End User: Research Institutes, Pharmaceutical Companies, Healthcare Facilities

Subsegments:

1) By BMS-813160: CCR5 Antagonist For HIV Treatment, CCR5 Antagonist For Inflammatory Diseases

2) By AG-1105: CCR5 Antagonist For Autoimmune Disorders, CCR5 Antagonist For Cancer Therapy

3) By DS-001: CCR5 Inhibitor For Cancer Treatment, DS-001 For Inflammatory Disease Management

4) By Other Types: Novel CCR5 Antagonists, Dual-Target CCR5 Antagonists

What Upcoming Trends Are Likely To Define The Future Path Of The CC Chemokine Receptor Type 5 Market?

Leading corporations within the CC chemokine receptor type 5 market are prioritizing the creation of novel medications, such as CCR5 antagonists, to secure a competitive edge. A CCR5 antagonist functions by obstructing the CC chemokine receptor type 5 (CCR5) receptor found on immune cells, which prevents specific pathogens like HIV from attaching and entering these cells, thereby impeding infection and influencing immune responses. For instance, in February 2024, CytoDyn Inc., a US-based biotechnology firm, declared that the U.S. Food and Drug Administration (FDA) had removed the clinical hold on leronlimab. This authorization allows the company to proceed with its intended HIV clinical trial to examine leronlimab’s impact on chronic inflammation. Leronlimab, also recognized as PRO 140 and categorized as a CCR5 antagonist, demonstrates considerable potential across diverse therapeutic applications due to its capacity to address multiple health issues and is currently under investigation for various conditions, including HIV and cancer.

Which Key Market Players Are Investing In Expansion And Innovation Within The CC Chemokine Receptor Type 5 Market?

Major companies operating in the cc chemokine receptor type 5 market are Cytodyn Inc., Gilead Sciences Inc., ViiV Healthcare Limited, Pfizer Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, AbbVie Inc., AstraZeneca plc, Novartis AG, Sanofi SA, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Ono Pharmaceutical Co Ltd, Avexa Limited, Incyte Corporation, Humanigen Inc., Biogen Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report

Which Regions Are Poised For Strategic Growth In The CC Chemokine Receptor Type 5 Market?

North America was the largest region in the CC chemokine receptor type 5 market in 2025. The regions covered in the cc chemokine receptor type 5 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized CC Chemokine Receptor Type 5 Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18290&type=smp

Browse Through More Reports Similar to the Global CC Chemokine Receptor Type 5 Market 2026, By The Business Research Company

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

C X C Chemokine Receptor 4 Cxcr4 Antagonists Market Report 2026

https://www.thebusinessresearchcompany.com/report/c-x-c-chemokine-receptor-4-cxcr4-antagonists-global-market-report

Chemoinformatics Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemoinformatics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795